Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

05/13/2013 | 07:15am US/Eastern

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014


June 2014

Annual Report ending on March 31st, 2014


Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales



Recommend :
React to this article
04/10 ONO PHARMACEUTICAL : Patent Issued for Compound Having Detrusor Muscle-Contracti..
03/27 ONO PHARMACEUTICAL CO., LTD. : ex-dividend day for final dividend
03/24 ONO PHARMACEUTICAL : FORXIGA® (dapagliflozin) receives regulatory approval in Ja..
03/06 ONO PHARMACEUTICAL CO., LTD. : ONO establishes an innovative research network ca..
02/19 ONO PHARMACEUTICAL CO., LTD. : "Method of Treating of Gastroesophageal Reflux Di..
01/29 ONO PHARMACEUTICAL CO., LTD. : "Methods of Producing Anamorelin Hydrochloride Ha..
2013 ONO PHARMACEUTICAL CO., LTD. : ONO Files for Regulatory Approval of "Nivolumab (..
2013 ONO PHARMACEUTICAL CO., LTD. : FDA Advisory Committee Recommends the Investigati..
2013 ONO PHARMACEUTICAL CO., LTD. : Clinical Trial Application submitted for Phase I ..
2013 ONO PHARMACEUTICAL CO., LTD. : AstraZeneca and Ono Enter Co-promotion Agreement ..
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Income Statement Evolution
ONO PHARMACEUTICAL CO., LT : Income Statement Evolution
More Financials
Dynamic quotes